星标 ★ IPO日报 精彩文章第一时间推送 单一产品贡献 根据招股书，汉方制药成立于2004年6月，是一家从事中医药产品生产、销售与研发的综合制药公司，专注于皮肤及黏膜疾病治疗领域。 汉方制药可以说是一家典型的家族控股企业，IPO前，公司股权高度集中，董事长秦文基持股90%，其弟、总经理秦银基持股10%。 2025年至2026年初，中医药企业赴港交所冲刺IPO呈现出加速态势，据统计，仅2025年9月21日至10月21日的一个月内，港交所就收到了17家医疗健康企 业的IPO申请，其中包括中药饮片头部企业四川新荷花。 进入2026年，这一趋势仍在延续。2026年2月25日，山东汉方制药股份有限公司（下称"汉方制药"）正式向港交所主板递交招股书，独家保荐人为中泰国 际。 张力制图 董事会由九名董事组成，包括秦文基、秦银基、秦文基之女Qin Chengxue教授等六名执行董事及三名独立非执行董事。公司执行董事、财务部负责人为王 春英女士。 结合财务数据来看，2023年、2024年及2025年前九个月，公司总收入分别为10.53亿元、9.92亿元及8.03亿元；同期净利润分别为2.37亿元、1.99亿元及1.45 亿元 ...

瑞财经 刘治颖2月25日，山东汉方制药股份有限公司（以下简称：汉方制药）向港交所主板递交上市申 请书，中泰国际为其独家保荐人。 招股书显示，汉方制药创立于2004年6月，是一家从事中医药产品的生产、销售与研发的综合制药公 司，专注于皮肤及黏膜疾病治疗领域。公司的产品组合分为三大类别：处方外用中成药，即公司的旗舰 产品复方黄柏液涂剂；经典配方中成药产品，即安宫牛黄丸及乌鸡白凤丸；及化妆品。 值得注意的是，汉方制药于2024年及2025年前9月宣派的股息分别为5000万元及1.5亿元，其中5000万元 及1.33亿元已于各期间派付。若以上述持股计算，2亿元分红均由秦氏兄弟分走。 秦文基，70岁，为汉方制药的联合创办人、董事长兼执行董事之一。汉方制药成立前，秦文基曾于1976 年至1987年期间于中国人民解放军服役。于1987年至1989年期间，秦文基于济南市生产资料服务公司工 作。于1989年至2004年，秦文基任职于济南深发经贸公司。秦文基曾于1980年1月至1980年11月期间， 在中国人民解放军昆明军区陆军学校参谋系指挥班完成课程。 秦银基，63岁，为汉方制药的共同创始人、总经理兼执行董事之一。创立汉方制药 ...

来源：企业上市 山东汉方制药股份有限公司在2026年2月25日正式递交上市申请：公司已向香港交易所主板提交上市申 请书，正式启动港股上市进程。 | 最新发布 | 申请人 | | --- | --- | | 日期 | | | 25/02/2026 | 山东汉方制药股份有限公司 | | | 25/02/2026 整体协调人公告-委任 [四 | | | 25/02/2026 申请版本(第一次呈交)全文档案 [四]多档案》 | 披露核心财务数据：伴随递表，其招股书公开。文件显示，该公司核心产品"复方黄柏液涂剂"在2024年 的销售收入位居中国外用中成药市场第四，市场份额为1.1%。中泰国际担任其独家保荐人。 简单来说，这家靠一款皮肤科中药涂剂做到市场前列的山东药企，已经正式踏上了赴港上市之路。 一家山东的药厂，靠一瓶独家生产的皮肤科中药"涂剂"（复方黄柏液涂剂）一年赚了近10个亿。现在准 备去香港上市（IPO），老板是秦家两兄弟，上市后家族仍然绝对控股。 核心干货解读 1. 我们是谁？靠什么赚钱？ 公司定位：一家把传统中医药和现代科学结合起来，专门做皮肤病和黏膜病用药的公司。 核心产品（摇钱树）：复方黄柏液涂剂。 市 ...

据港交所2月25日披露，山东汉方制药股份有限公司（简称"汉方制药"）向港交所主板提交上市申请 书，中泰国际为其独家保荐人。 招股书显示，汉方制药是一家从事中医药产品的生产、销售与研发的综合制药公司。公司专注于皮肤及 黏膜疾病治疗领域，善于将传统中医智慧与现代医药科学相融合。根据弗若斯特沙利文的资料，按2024 年销售收入计，复方黄柏液涂剂在中国外用中成药市场排名第四，占据1.1%的市场份额。在此成熟产 品的成功基础上，公司正透过提供化妆品及其他中成药产品拓展产品组合。 汉方制药的旗舰产品复方黄柏液涂剂为目前中国中成药领域中唯一获批的处方涂剂，其为国家二级中药 保护品种，根据《中药品种保护条例》，该认定授予其独家保护，依法禁止任何其他实体生产相同药 品。该国家二级保护地位使公司享有复方黄柏液涂剂的独家市场地位，而无相同药品构成直接竞争。 报告期内，公司来自五大客户的收入分别占各期总收入的56.1%、55.9%及55.0%。其中，最大客户的收 入占比均在20%以上。 汉方制药的收入主要透过销售三类产品产生：外用中成药即复方黄柏液涂剂；化妆品；经典方剂中成药 产品即安宫牛黄丸。复方黄柏液涂剂是其最大的单一产品，报告 ...

据港交所2月25日披露，山东汉方制药股份有限公司(简称：汉方制药)向港交所主板递交上市申请书，中泰国际为其独家保荐人。 公司简介 招股书显示，汉方制药是一家从事中医药产品的生产、销售与研发的综合制药公司。公司专注于皮肤及黏膜疾病治疗领域，善于将 传统中医智慧与现代医药科学相融合。根据弗若斯特沙利文的资料，按2024年销售收入计，复方黄柏液涂剂在中国外用中成药市场 排名第四，占据1.1%的市场份额。在此成熟产品的成功基础上，公司正透过提供化妆品及其他中成药产品拓展产品组合。 汉方制药的旗舰产品复方黄柏液涂剂为目前中国中成药领域中唯一获批的处方涂剂，其为国家二级中药保护品种，根据《中药品种 保护条例》，该认定授予其独家保护，依法禁止任何其他实体生产相同药品。该国家二级保护地位使公司享有复方黄柏液涂剂的独 家市场地位，而无相同药品构成直接竞争。 作为市场领导者，汉方制药认为复方黄柏液涂剂将受惠于稳定增长的市场，巩固公司的竞争地位。在复方黄柏液涂剂的成功奠定的 基础之上，公司通过三大核心战略积极推进多元化产品组合：(i)推进新型中成药产品研发；(ii)将经临床验证的医疗机构制剂或临床 经验方转化为创新型、具备上市条件 ...

智通财经APP获悉，据港交所2月25日披露，山东汉方制药股份有限公司(简称：汉方制药)向港交所主板递交上市申请书，中泰国际 为其独家保荐人。 公司简介 招股书显示，汉方制药是一家从事中医药产品的生产、销售与研发的综合制药公司。公司专注于皮肤及黏膜疾病治疗领域，善于将 传统中医智慧与现代医药科学相融合。根据弗若斯特沙利文的资料，按2024年销售收入计，复方黄柏液涂剂在中国外用中成药市场 排名第四，占据1.1%的市场份额。在此成熟产品的成功基础上，公司正透过提供化妆品及其他中成药产品拓展产品组合。 汉方制药的旗舰产品复方黄柏液涂剂为目前中国中成药领域中唯一获批的处方涂剂，其为国家二级中药保护品种，根据《中药品种 保护条例》，该认定授予其独家保护，依法禁止任何其他实体生产相同药品。该国家二级保护地位使公司享有复方黄柏液涂剂的独 家市场地位，而无相同药品构成直接竞争。 作为市场领导者，汉方制药认为复方黄柏液涂剂将受惠于稳定增长的市场，巩固公司的竞争地位。在复方黄柏液涂剂的成功奠定的 基础之上，公司通过三大核心战略积极推进多元化产品组合：(i)推进新型中成药产品研发；(ii)将经临床验证的医疗机构制剂或临床 经验方转化 ...

Core Viewpoint - The article highlights the significance of the "ghost market" in Anguo, Hebei Province, as a crucial hub for traditional Chinese medicine, particularly for well-known brands like Tong Ren Tang, which rely on local medicinal materials for their products [1] Group 1: Market Dynamics - The "ghost market" operates on specific lunar calendar dates, attracting merchants and buyers from various regions to trade medicinal materials [1] - The market's nighttime trading practices have earned it the nickname "ghost market" among locals [1] Group 2: Quality Assurance - Liu Tianliang, a chief technician in herbal material identification at Tong Ren Tang, emphasizes the importance of on-site visits to the market every six months to assess the quality and yield of medicinal materials [1] - The rapid advancement of technology has led to increased instances of fraud and adulteration in the herbal material market, making practical research essential for material identification [1]

Core Viewpoint - The Chinese patent medicine industry is facing increased scrutiny and regulatory challenges, particularly regarding pricing disparities and the misuse of traditional medicine prescriptions, necessitating a shift towards genuine innovation and responsible practices [1][2][3]. Group 1: Regulatory Environment - The Tianjin Medical Insurance Bureau has initiated price risk management for 230 Chinese patent medicine varieties, revealing price discrepancies as high as 3042 times among different products [1]. - The regulatory environment for Western medicine is becoming stricter, with the National Medical Products Administration (NMPA) enforcing quality and efficacy evaluations, while Chinese patent medicine companies have been able to evade similar scrutiny [2]. - There is a growing concern about the misuse of Chinese patent medicines, with some hospitals excessively prescribing these medications, leading to calls for stricter regulations on who can prescribe them [1][2]. Group 2: Industry Challenges - The Chinese patent medicine industry has rapidly developed into a market exceeding 400 billion yuan, but it has been marred by over-marketing and misinterpretation of "integrated Chinese and Western medicine" [2]. - The reliance on "micro-innovation" and "pseudo-innovation" is becoming unsustainable as regulatory standards tighten, pushing companies to seek true innovation rather than minor adjustments to existing products [2][3]. - The era of inflated pricing and high profits for Chinese patent medicines is coming to an end, prompting leading companies to explore transitions into broader health product markets [3]. Group 3: Recommendations for the Industry - Companies are advised to move away from superficial innovations and focus on developing new medicinal materials, formulations, and delivery methods to meet stricter regulatory requirements [2][3]. - A return to the principles of "differentiated treatment" in traditional Chinese medicine is recommended, with a call for the NMPA to limit the scope of indications for Chinese patent medicines to prevent misuse [3]. - The industry should shift from being solely a medical insurance product to a broader health product, targeting preventive care for populations at risk of health issues [3].

Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. is undergoing a stock issuance process, facing inquiries from the Shenzhen Stock Exchange regarding its financial matters and business operations [1] Financial Performance - The company reported revenues of 385.77 million yuan, 422.71 million yuan, 441.46 million yuan, and 97.61 million yuan over the reporting periods, with net profits of 132.18 million yuan, -354.23 million yuan, -199.54 million yuan, and -30.42 million yuan, indicating continuous losses [2] - The shift from generic to innovative drugs has led to increased R&D expenses and a decline in gross margins due to the inclusion of antiviral drugs in the national centralized procurement list, resulting in a 33.33% decrease in drug sales prices in 2023 compared to 2022 [2] - The gross margins over the last three years were 18.54%, 2.59%, and 8.57% [2] Procurement and Inventory - The procurement amounts from the top five suppliers were 39.34 million yuan, 97.64 million yuan, 79.83 million yuan, and 7.89 million yuan, with respective proportions of 39.86%, 56.57%, 60.53%, and 50.64% of total procurement [3] - The company has adopted a sales-driven production model, with significant increases in prepayments due to the sales of its product, Taizhongding [3] - Inventory values at the end of each period were 68.66 million yuan, 111.48 million yuan, 114.48 million yuan, and 121.13 million yuan, with a substantial increase in inventory impairment provisions expected due to product expiration [3] R&D and Financial Ratios - The number of R&D personnel decreased from 112 to 76, while R&D expenses were 185.46 million yuan, 132.96 million yuan, 44.05 million yuan, and 6.10 million yuan, with a declining R&D expense ratio [4] - The asset-liability ratios were 36.07%, 64.74%, 72.42%, and 73.45%, with a significant increase in 2023 due to financial liabilities recognized from a subsidiary's capital increase [4] - The liquidity ratios (current and quick) were consistently below industry averages, indicating potential liquidity challenges [4] Fundraising Projects - The company plans to raise 976.87 million yuan, with allocations of 598.38 million yuan for innovative drug R&D, 88.49 million yuan for traditional Chinese medicine industrialization, and 290 million yuan for working capital [5] - The innovative drug R&D project includes two drugs for chronic hepatitis B treatment, with significant capital expenditures planned for their development [5] - The traditional Chinese medicine project aims to acquire drug approvals for new products, with an expected internal rate of return of 23.22% [5] Previous Fundraising - Previous fundraising of 514 million yuan has been fully utilized, with some funds redirected due to unmet expectations from prior projects [6] - The company faces challenges in transitioning to innovative drugs, but successful implementation of fundraising projects could provide new growth opportunities [6]

Investment Rating - The report indicates a positive outlook for the gynecological menstrual regulation medications industry in China, driven by increasing female health awareness and supportive policies [3]. Core Insights - The gynecological menstrual regulation medications industry in China has shown steady growth, supported by rising demand and policy benefits, with a focus on women's health needs [3]. - The market is expected to expand further due to the emergence of the "she economy" and the aging population, highlighting the potential in menopause management and reproductive health segments [3]. - The industry is characterized by a dual approach of Western and traditional Chinese medicine, with Western medications primarily consisting of hormone-based drugs and Chinese medicine focusing on holistic treatment [4][5]. Summary by Sections Industry Overview - Menstrual disorders are common among women, with significant differences in treatment approaches between Western and Chinese medicine [4]. - The report defines gynecological menstrual regulation medications as those that adjust reproductive endocrine functions or overall physiological functions to restore normal menstrual cycles [35][36]. Market Size - The market for gynecological menstrual regulation medications is projected to reach 238.9 billion yuan in 2024, with a growth forecast to 312.8 billion yuan by 2029 [43]. - The growth is attributed to increased awareness of women's health and rising incidence of gynecological diseases, particularly among younger women [43][44]. Industry Chain Analysis - The upstream analysis indicates that rising raw material prices are increasing production costs, with leading companies showing resilience due to resource advantages [53][54]. - The midstream analysis reveals a stable growth in the market driven by consumer demand, with a concentration of market share among leading brands [57][61]. - The downstream analysis highlights the growth of online channels, providing significant development opportunities for the industry [65]. Competitive Landscape - The competitive landscape shows a mix of established companies and smaller players, with leading firms leveraging brand strength and distribution advantages [61][62]. - The report notes that traditional Chinese medicine products dominate the market, while Western medications are gaining traction due to their targeted treatment capabilities [43][44].